Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early intratracheal dornase alfa to prevent ARDS after severe trauma
2018-000654-22Phase 3Active
- Sponsor
- Strasbourg University Hospital
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dornase alfa in acute respiratory distress syndrome (ARDS) and polytrauma (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Incidence of moderate to severe ARDS within first 7 days. Started Jun 2018; status: active.
02
Drugs
dornase alfa
03
Conditions
acute respiratory distress syndrome (ARDS)polytrauma
Beyond the preview
Go deeper on 2018-000654-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000654-22.